On January 20, 2026, Pliant Therapeutics (NASDAQ:PLRX) witnessed a significant insider transaction when its Chief Financial Officer, Keith Lamont Cummings, sold 24,002 shares of the company's common stock. The sale was executed at an average price of $1.28 per share, summing to a total value of $30,722, as indicated in a Form 4 filing submitted to the Securities and Exchange Commission.
The share price for these transactions ranged between $1.245 and $1.33, reflective of the prevailing market conditions. Post-sale, Cummings retains direct ownership of 297,214 shares in Pliant Therapeutics.
During the preceding year, Pliant Therapeutics' stock has experienced a substantial decline, losing nearly 88% of its value. Currently, the company trades near a 52-week low of $1.10, contributing to a market capitalization of approximately $80 million. Despite these financial difficulties, including a negative earnings per share of -$2.87, analysis using InvestingPro's tools suggests the stock may be undervalued. Investors interested in deeper analysis and strategic insights regarding PLRX can explore additional ProTips ahead of the company's next earnings report slated for March 3, 2026.
Beyond stock movements, Pliant Therapeutics has recently shared encouraging data from a Phase 1 clinical trial involving its cancer treatment candidate PLN-101095. The trial, which combined PLN-101095 with the immunotherapy agent pembrolizumab, targeted patients with advanced solid tumors resistant to other immune checkpoint inhibitors. Results demonstrated promising anti-tumor activity, including one complete response and three partial responses among patients with diverse cancers such as cholangiocarcinoma, melanoma, and non-small cell lung cancer.
On the organizational front, Pliant Therapeutics has appointed Minnie Kuo as chief operating officer, succeeding her previous role as chief development officer since September 2023. Additionally, the company has announced the impending departure of its chief medical officer, Dr. Éric Lefebvre, who will assist during the transition period in a consultancy role. Hans Hull, the chief business officer, has also resigned; however, the company clarified that this exit was unrelated to any disagreements about operational matters. These leadership changes signify ongoing strategic shifts within Pliant Therapeutics as it navigates operational and clinical development challenges.